Efficacy of Tecovirimat and Cidofovir Against MPXV-Induced Pneumonia, Skin Lesion, and Arthritis in the High-Risk Population-Relevant SCID Mouse Model
Abstract
On
February
27,
2025,
WHO
maintained
monkeypox
as
a
PHEIC
following
its
third
round
of
assessment.
Human
virus
infection
primarily
manifests
with
fever,
lymphadenopathy,
and
rash.
Severe
cases
may
develop
pneumonia,
encephalitis,
myocarditis
arthritis.
After
evaluation
three
murine
models
(ICR,
IFNAR1−/−,
SCID),
we
identified
SCID
mice
stable
hosts
for
clade
IIb,
modeling
high-risk
populations
like
patients
HIV.
Three
models,
characterized
by
rash,
arthritis,
were
established
the
pharmacodynamic
tecovirimat
cidofovir.
Both
drugs
decreased
titer
in
target
organs
during
early
ensured
100%
survival.
As
limitation,
cidofovir
failed
to
inhibit
viral
DNA
load
skin
lesions,
monotherapy
or
was
ineffective
prolonged
intradermal
infections.
These
data
indicate
that
therapeutic
efficacy
is
contingent
upon
distinct
disease
phenotypes
progression
stages,
underscoring
necessity
novel
interventions
against
monkeypox.
Research Square (Research Square), Journal Year: 2025, Volume and Issue: unknown
Published: April 23, 2025
Language: Английский